Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 6, 2022; 10(19): 6349-6359
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6349
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6349
Figure 1 Prevalence of primary Helicobacterpylori resistance to antibiotics in China, Japan, and South Korea.
CAM: Clarithromycin; MDZ: Metronidazole; LVFX: Levofloxacin; AMX: Amoxicillin; TET: Tetracycline.
- Citation: Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359
- URL: https://www.wjgnet.com/2307-8960/full/v10/i19/6349.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i19.6349